AI for Contract Review in Pharma

A contract in this industry does three jobs at once. It is commercial, in the ordinary way. It is regulatory, because it fixes who is accountable for a GxP activity an inspector will later ask about, and because a signature can create a transfer of value somebody has to report. And it is scientific, because it allocates ownership of inventions that do not exist yet.

This piece is about the contracting desk inside a sponsor or manufacturer: clinical trial agreements, quality and technical agreements, supply terms, safety data exchange, licensing, and the confidentiality agreements that precede all of them. It is not about payer or provider side contracting.

The site by site negotiation against a protocol that will not move

One protocol goes to many sites. The protocol is fixed. The contract is not, and every institution has its own template, its own legal office, its own immovable positions and its own queue. The same handful of clauses gets renegotiated in parallel, and the measure everyone reports on is days to site activation.

An agent's first useful job is to read each returned site template against the sponsor's position set and classify every deviation: acceptable as drafted, acceptable with the standard fallback, requires the sponsor's legal owner. That classification is the bottleneck, not the drafting. It also recognises when a site raises a point another site raised last month and surfaces what was agreed then, which is memory a start up team never has time to build.

The budget schedule and the invoices that arrive against it

Site budgets are negotiated separately from the legal terms, often by a different team. Per patient amounts sit in a schedule broken out by visit, with separate lines for screen failures, unscheduled visits, pass through costs, start up and archiving fees, and an overhead rate applied to some of those lines but not all.

An agent turns each executed schedule into structured line items with their trigger conditions, then holds that against what the site later invoices and what the clinical system says happened. The mismatches are the point: a procedure billed that the schedule folds into the visit fee, a screen failure claimed at the full visit rate, a milestone invoiced before its trigger. Once the reading is done that comparison is arithmetic, and it belongs in ordinary code.

Indemnity, insurance and subject injury compensation

This is where sites push back hardest and sponsor positions are least flexible. The negotiation turns on narrow things: whether indemnity survives a protocol deviation, whether investigator negligence is carved out and how broadly, whether subject injury compensation follows a named national guideline or the contract's own wording, whether the sponsor's insurance certificate satisfies a local requirement on amount and territory.

An agent compares the site's language against the approved positions and produces the fallback already agreed elsewhere. What it cannot do is decide whether an unfamiliar formulation is acceptable. That goes to the risk owner with both texts side by side.

Publication rights and the sponsor review window

The publication clause is a commercial negotiation with a scientific consequence. It governs how long the sponsor may review a manuscript before submission, whether that window extends to allow a patent filing, whether the sponsor may strike confidential information, and whether an investigator may publish single site results ahead of the multicentre paper.

These clauses drift. Sites amend the review period, remove the extension for patent filing, or reserve rights the template does not grant. An agent maintains the extracted position across a study, so the medical team can say without opening files which sites hold the standard window and what the others agreed.

Confidentiality agreements at volume, in both directions

Every partnering conversation, every feasibility exercise, every vendor assessment starts with a confidentiality agreement, and they arrive faster than anyone reads them properly. The clauses that matter are consistent: the definition of confidential information and whether it reaches residual knowledge in people's heads, survival for trade secrets, the carve out for independently developed work, and any language reaching inventions or exclusivity.

An agent reviews these against the standard position, marks the two or three deviations that are real, and routes the rest through. Volume is what makes that worth automating. Judgement on residuals and on anything touching future invention ownership is not, and should not be.

Quality agreements, supply terms and the gap between them

A quality agreement sits alongside the supply agreement with a contract manufacturer or laboratory and allocates GxP responsibility line by line: who releases, who approves deviations, who owns stability programmes, who notifies whom of a regulatory inspection and within what period, who controls subcontracting.

The failure mode is drift. The supply agreement is amended for commercial reasons and the quality agreement is not, or a change to the quality agreement creates a responsibility the supply agreement does not fund. An agent holds both as structured responsibility matrices and reports where they disagree: an activity assigned to both parties, an activity assigned to neither, contradictory notification periods, a term extended on one side.

Capacity and change control

The commercial side carries obligations that behave like operational commitments. Minimum purchase and capacity reservation terms, forecast horizons and the portion that becomes binding, notice periods for a change in manufacturing process or site, approval rights over change control, and what a failure to supply entitles you to. In a register those become dates and thresholds supply chain can act on rather than clauses nobody reads until a change notice arrives.

Safety data exchange and the obligation nobody mapped

A pharmacovigilance agreement defines how safety information moves between two organisations: which events are reportable, in which direction, on what clock and from which starting point, who submits to which authority, how reconciliation is performed and how often, and who screens the literature.

A single obligation in that document with no corresponding step in an operating procedure is an inspection finding. An agent extracts every exchange obligation as a structured rule with its trigger, direction, timeline and owner, then holds that set against the procedures meant to implement it. Unmapped obligations come out as a list. Closing them is human work, and so is judging whether a mapped step genuinely satisfies the clause.

Licensing terms and what survives termination

Licensing, in licensing and collaboration agreements carry the most durable obligations in the company and the least accessible ones. Field and territory definitions with their carve outs, milestones with their trigger events, royalty rates with stacking and step down provisions, diligence obligations expressed as effort standards, and the clauses that survive termination: licences that continue, data returned, rights that revert.

An agent builds the structured deal terms from the executed set, which matters most once the people who negotiated it have moved on. It cannot tell you whether a milestone has been achieved. It can tell you the wording of the trigger and who was named responsible.

Engagements with healthcare professionals

Advisory boards, speaker arrangements, consultancy and investigator initiated research produce agreements at volume, each with a compliance tail. The fee has to be defensible against a fair market value framework, the scope has to be real, and the payment becomes a reportable transfer of value whose attributes must be captured at contracting rather than reconstructed later.

An agent extracts the reporting relevant fields from each executed agreement and its payment records, checks them for internal consistency, and flags those that will not reconcile. Whether a given fee is appropriate is a compliance decision and stays one.

Clinical and real world data terms

Data clauses here turn on specific things: where clinical and real world data may be processed, what the sponsor may do with it beyond the study, and what happens to samples afterwards.

The questions worth extracting are concrete. May data be transferred outside the country of collection, and on what basis. Is secondary use permitted, and is it limited to the indication. Are samples retained, for how long, and for what analyses. Who owns results derived from a site's data. An agent maintains those answers per agreement, so a proposed analysis can be checked against what was agreed rather than what everyone assumes.

The obligation register, and the amendments that change it

Here the post signature obligations are the substance, and several functions own them at once. Clinical operations owns site activation commitments. Quality owns notification duties. Regulatory owns filing obligations. Finance owns milestones. Legal owns none of them and holds all the documents.

The deliverable is a register naming each obligation, its source clause, its trigger, its deadline and its owning function. An agent builds the first version from the executed set and keeps it current as agreements are signed.

The executed set is the truth

Nobody has read all of it. A master agreement with years of amendments, work orders and side letters has no current state anyone can see, and the amendment that moved a notification period is three documents deep. An agent assembles the effective position clause by clause, citing the version behind every value, and reports contradictions rather than picking a winner.

Where AI fails here

Regulatory and compliance judgement is out of scope. Whether an arrangement satisfies a transparency requirement, whether a data transfer is lawful, whether a safety obligation is adequately implemented: these are decisions for counsel and quality, and the right output is an escalation quoting the wording.

Novel drafting is not extraction. An unfamiliar indemnity formulation from an institution you have not worked with needs a lawyer, and a system that produces a confident fallback for it is doing harm.

The register decays without maintenance. A quality agreement responsibility read from a superseded version is worse than no answer, because somebody will rely on it. Amendments have to flow in continuously and every value should show its source version.

Source quality limits everything. Scanned site templates, redlines exchanged as flattened files and budgets held in spreadsheets extract less reliably than clean documents. Measure accuracy on those inputs separately rather than averaging it into one figure.

Speed is not activation. An agent that clears legal review faster does not fix an ethics committee queue, a backlog in the institution's own contracting office, or an approval waiting on a weekly meeting. Measure the whole path or you will claim an improvement nobody can feel.

Proving it on one study

Take a single protocol and run the agent alongside the team already negotiating it. Compare its deviation classifications against theirs on agreements already finished, where the answer is known, then extend it to that study's budget schedules against invoices already paid. What comes out is an accuracy figure you measured yourself, and a team that has seen where the system is wrong. If that is your problem, hello@adoptaipartners.com reaches us.